ISRCTN24454186进行中(未招募)未知
Stratification in Alzheimer's disease
lster University0 个研究点目标入组 600 人开始时间: 2017年11月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •Inclusion criteria for age of onset Alzheimer’s disease patients:
- •1. Male and female participants
- •2. Aged between 45-84
- •3. Diagnosis of Alzheimer’s disease (50 aged 45-54, 50 aged 55-64, 50 aged 65-74, 50 aged 75-84)
- •Inclusion criteria for ‘other dementia’ group in age of onset study:
- •1. Male and female participants
- •2. Aged between 45-84
- •3. With an ‘other’ diagnosis of dementia (i.e. NOT Alzheimer’s disease) including but not limited to: Vascular Dementia (VaD), Frontotemporal dementia (FTD), Dementia with Lewy Bodies (DLB)
- •Inclusion criteria for MCI group in age of onset study:
- •1. Male and female participants
- •2. Aged between 45-84
- •3. A diagnosis of Mild Cognitive Impairment (MCI)
- •Inclusion criteria for apparently healthy cohort in age of onset study:
- •1. Men and women
- •2. Aged between 45-84 (50 aged 45-54, 50 aged 55-64, 50 aged 65-74, 50 aged 75-84)
- •Inclusion criteria for imaging sub study:
- •1. Men and women
- •2. Aged 45-84
- •3. Diagnosis of MCI, Alzheimer’s disease, other dementia and healthy controls (25 per group)
排除标准
- •Exclusion criteria for all age of onset participants:
- •Participants with a bleeding disorder, for which, blood sampling would not be advisable.
- •Exclusion criteria for imaging sub study:
- •1. Participants with a bleeding disorder, for which blood sampling would not be advisable
- •2. Pregnancy
- •3. Previous head or neck surgery
- •4. Suffer from epilepsy or migraine
- •5. Active implants (pacemaker, neurostimulator, insulin pump, ossicular prosthesis)
- •6. May have metal fragments in the body
- •7. Have jewellery/piercings that cannot be removed
- •8. Suffer from claustrophobia
研究者
相似试验
招募中
不适用
Establishment of dementia onset and progression model considering relevant high-risk genes after COVID-19 infection in dementia high-risk groupMental and behavioural disordersKCT0007688The Catholic University of Korea, Seoul St. Mary's Hospital65
进行中(未招募)
1 期
The GLP-1 receptor agonist liraglutide can slow down the progression of Alzheimer’s diseaseMedDRA version: 14.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersAlzheimer's diseaseEUCTR2011-000794-31-DKDept. of Pharmacology
已完成
不适用
ongitudinal study across the spectrum of Alzheimer's disease associated with amyloid PET Imagings diseaseAlzheimer's diseaseJPRN-UMIN000014346Shonan-Atsugi hospital160
进行中(未招募)
1 期
Can a common blood pressure drug, losartan, help in Alzheimer's disease?Alzheimer's DiseaseEUCTR2012-003641-15-GBorth Bristol NHS Trust228
已完成
不适用
Alzheimer's disease, cognition and cerebrospinal fluid: Are they associated?Effect of anaesthesia and surgery on cognitionCerebrospinal fluid (CSF) predictors of cognitive change and Alzheimer's diseaeAnaesthesiology - AnaestheticsNeurological - Alzheimer's diseaseMental Health - Studies of normal psychology, cognitive function and behaviourAlzheimer's DiseaseACTRN12612000493842St. Vincent's Hospital54
